Early Release

Early Release / Review Article

Prof. Dr. Abdülkadir Noyan: Professional and Academic Aspects

Turhan Ada

Most Read

  1. Pneumococcal Vaccine as One of the Immunization Coverage Targets for Adulthood Vaccines: A Consensus Report of the Study Group for Adult Immunization of the Turkish Society of Clinical Microbiology and Infectious Diseases
  2. Does Hepatitis B Affect Erectile Dysfunction and Lower Urinary Tract Symptoms?
  3. HIV Infection in Turkey: How Close Are We to the Target?
  4. Evaluation of HBeAg-Negative Chronic Hepatitis B Patients Who Had Undergone Liver Biopsy in Accordance With the Guidelines
  5. Diagnosis, Treatment and Prevention of Diabetic Foot Wounds and Infections: Turkish Consensus Report
  6. When to Stop Antiviral Therapy in Chronic Hepatitis B
  7. Mycoplasma hominis and Ureaplasma urealyticum: Their Role in Urogenital System Infections and Retrospective Evaluation of Antibiotic Resistance Rates
  8. Crimean-Congo Haemorrhagic Fever: Treatment and Use of Ribavirin
  9. Modern Diagnostic Methods Used in Bacteriology: Rapid and Effective
  10. Analysis of HIV/AIDS-Related Stigma and Discrimination in Turkey: Results of the People Living With HIV Stigma Index

Volume 33, Issue 1

Original Article

HIV/AIDS Cohort Evaluation of a Single Center in the Context of “90-90-90” Targets

Heval Can Bilek
Affiliations
  • Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Samsun, Türkiye
,
Aydın Deveci
Affiliations
  • Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Samsun, Türkiye
,
Esra Aksakal-Tanyel
Affiliations
  • Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Samsun, Türkiye
  • 909090 targets
  • HIVAIDS
  • viral suppression

Objective: Human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) continues to be one of the most important health, social and safety issues faced by the global community. In 2014, the United Nations HIV/AIDS joint program (UNAIDS) proposed a new target for global antiretroviral treatment (ART) program. This new target, known as “90-90-90”, recommends that by 2020, 90% of all people living with HIV will be knowing their HIV serology, 90% of all people with diagnosed HIV infection will be receiving ART and 90% of all people on ART will achieve viral suppression. The aim of our study was to evaluate the HIV/AIDS cohort data of our clinic in the context of “90-90-90” targets.

Methods: The medical records of HIV-infected patients followed in the Department of Infectious Diseases and Clinical Microbiology Ondokuz Mayıs University Faculty of Medicine between 2005 and 2018 were reviewed retrospectively.

Results: In our clinic, 336 HIV-infected patients were followed during the study period. Of these patients, 284 (84.5%) were male. Of the 317 surviving patients, 240 (75.7%) were examined at the outpatient clinic at least once within the last 6 months and 239 (75.3%) were on ART. According to the latest laboratory results of 239 patients on ART, virological suppression was achieved in 206 (86.1%) patients. In the analysis of 33 patients with a detectable viral load on ART, it was found that 11 patients were on ART for less than 6 months, 8 patients did not use their medication regularly, and one patient did not have a test result.

Conclusions: Although it was determined that “90-90-90” targets are achievable within the scope of the patient group that we serve in our hospital, the compilation of nationwide data and screening programs to identify all HIV-infected patients in the community, will be guiding to achieve “90-90-90” targets.

Klimik Dergisi 2020; 33(1): 67-70.

Cite this article as: Bilek HC, Deveci A, Aksakal-Tanyel E. [HIV/AIDS cohort evaluation of a single center in the context of “90-90-90” targets]. Klimik Derg. 2020; 33(1): 67-70. Turkish.

  • 67-70
  • 10.5152/kd.2020.13
  • April 29, 2020
  • 1653
  • 722
Download as PDF
  • This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. CC BY-NC
Volume 37, Issue 3 Volume 37, Issue 2 Volume 37, Issue 1 Volume 36, Issue 4 Volume 36, Supplement 1 Volume 36, Issue 3 Volume 36, Issue 2 Volume 36, Issue 1 Volume 35, Issue 4 Volume 35, Issue 3 Volume 35, Issue 2 Volume 35, Issue 1 Volume 34, Issue 3 Volume 34, Issue 2 Volume 34, Issue 1 Volume 33, Issue 3 Volume 33, Issue 2 Volume 33, Issue 1 Volume 32, Issue 3 Volume 32, Supplement 1 Volume 32, Supplement 2 Volume 32, Issue 2 Volume 32, Issue 1 Volume 31, Issue 3 Volume 31, Issue 2 Volume 31, Supplement 1 Volume 31, Issue 1 Volume 30, Issue 3 Volume 30, Issue 2 Volume 30, Supplement 1 Volume 30, Issue 1 Volume 29, Issue 3 Volume 29, Issue 2 Volume 29, Issue 1 Volume 28, Supplement 1 Volume 28, Issue 3 Volume 28, Issue 2 Volume 28, Issue 1 Volume 27, Supplement 1 Volume 27, Issue 3 Volume 27, Issue 2 Volume 27, Issue 1 Volume 26, Issue 3 Volume 26, Supplement 1 Volume 26, Issue 2 Volume 26, Issue 1 Volume 25, Issue 3 Volume 25, Issue 2 Volume 25, Issue 1 Volume 24, Issue 3 Volume 24, Issue 2 Volume 24, Issue 1 Volume 23, Issue 3 Volume 23, Issue 2 Volume 23, Issue 1 Volume 22, Issue 3 Volume 22, Issue 2 Volume 22, Issue 1 Volume 21, Issue 3 Volume 21, Supplement 2 Volume 21, Supplement 1 Volume 21, Issue 2 Volume 21, Issue 1 Volume 20, Issue 3 Volume 20, Supplement 2 Volume 20, Issue 2 Volume 20, Issue 1 Volume 20, Supplement 1 Volume 19, Issue 3 Volume 19, Issue 2 Volume 19, Issue 1 Volume 18, Issue 3 Volume 18, Supplement 1 Volume 18, Issue 2 Volume 18, Issue 1 Volume 17, Issue 3 Volume 17, Issue 2 Volume 17, Issue 1 Volume 16, Issue 3 Volume 16, Issue 2 Volume 16, Issue 1 Volume 1, Supplement 1 Volume 15, Issue 3 Volume 15, Issue 2 Volume 15, Issue 1 Volume 14, Issue 3 Volume 14, Issue 2 Volume 14, Issue 1 Volume 13, Issue 3 Volume 13, Issue 2 Volume 13, Supplement 1 Volume 13, Issue 1 Volume 12, Issue 3 Volume 12, Issue 2 Volume 12, Issue 1 Volume 11, Issue 3 Volume 11, Issue 2 Volume 11, Supplement 1 Volume 11, Issue 1 Volume 10, Issue 3 Volume 10, Issue 2 Volume 10, Issue 1 Volume 9, Issue 3 Volume 9, Issue 2 Volume 9, Issue 1 Volume 8, Issue 3 Volume 8, Issue 2 Volume 8, Issue 1 Volume 6, Issue 3 Volume 7, Issue 1 Volume 7, Issue 2 Volume 7, Issue 3 Volume 4, Issue 3 Volume 5, Issue 1 Volume 5, Issue 2 Volume 5, Issue 3 Volume 6, Issue 1 Volume 6, Issue 2 Volume 3, Issue 1 Volume 3, Issue 2 Volume 3, Issue 3 Volume 4, Issue 1 Volume 4, Issue 2 Volume 1, Issue 2 Volume 2, Issue 1 Volume 2, Issue 2 Volume 2, Issue 3 Volume 1, Issue 1